MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors-Reference-Cited by-同舟云学术

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors

Published:2022-12 Issue:6 Volume:7 Page:100646
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Vicier C.,Isambert N.,Cropet C.,Hamimed M.,Osanno L.,Legrand F.,de La Motte Rouge T.,Ciccolini J.,Gonçalves A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials;Kohrt;J Immunother Cancer,2016

2. Inhibitory B7-family molecules in the tumour microenvironment;Zou;Nat Rev Immunol,2008

3. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses;Butte;Immunity,2007

4. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo;Paterson;J Immunol,2011

5. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways;Fife;Immunol Rev,2008

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial;Nature Medicine;2024-07-05

2. A comprehensive bibliometric analysis (2000–2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer;Frontiers in Pharmacology;2024-05-10

3. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors;Cancer Immunology, Immunotherapy;2024-02-13

4. METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors;European Journal of Cancer;2024-02

5. Metronomic chemotherapy, dampening of immunosuppressive cells, antigen presenting cell activation, and T cells. A quartet against refractoriness and resistance to checkpoint inhibitors;Cancer Letters;2023-11